Insulin lispro

For patient information, click here
Insulin lispro (marked by Lilly as "Humalog®") is a fast acting insulin analogue; it was the first insulin analogue.

It was engineered through recombinant DNA technology so that the penultimate lysine and proline residues on the C-terminal end of the B-chain were reversed. This modification did not alter receptor binding, but blocked the formation of insulin dimers and hexamers. This allowed larger amounts of active monomeric insulin to be available for postprandial (after meal) injections.